Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
739.66B
Market cap739.66B
Price-Earnings ratio
64.56
Price-Earnings ratio64.56
Dividend yield
0.72%
Dividend yield0.72%
Average volume
3.24M
Average volume3.24M
High today
$783.55
High today$783.55
Low today
$773.00
Low today$773.00
Open price
$780.30
Open price$780.30
Volume
1.45M
Volume1.45M
52 Week high
$972.53
52 Week high$972.53
52 Week low
$677.09
52 Week low$677.09

LLY News

TipRanks 10h
Eli Lilly’s Pioneering Study on Lasmiditan for Pediatric Migraine Relief: A Market Game-Changer?

Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks Premium at 5...

TipRanks 2d
Tests Show Eli Lilly’s Weight-Loss Pill Works as Well as Injection

Preliminary test results show that Eli Lilly’s (LLY) daily weight-loss pill, called Orforglipron, is as effective as the company’s injectable GLP-1 drug Zepboun...

TipRanks 3d
Eli Lilly Stock Consolidates in Value Territory

Eli Lilly (LLY) has recently become a core holding in my portfolio, and current market conditions present an attractive opportunity to initiate or expand a posi...

Analyst ratings

83%

of 30 ratings
Buy
83.3%
Hold
10%
Sell
6.7%

More LLY News

Seeking Alpha 4d
Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

Novo Nordisk (NVO) and Eli Lilly & Co. (NYSE:LLY), the global leaders in obesity medications, are now facing their first major competitor in China. Suzhou-base...

Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.